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A B S T R A C T
Purpose: To evaluate the efﬁcacy and safety of lacosamide administered as either ﬁrst add-on or later
add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS).
Methods: In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titrated to
400 mg/day) either as add-on to ﬁrst AED monotherapy, or as later add-on to 1–3 concomitant AEDs after
2 previous AEDs. The primary efﬁcacy variable was the proportion of patients achieving seizure
freedom for the ﬁrst 12 weeks of the 24-week Maintenance Phase.
Results: 456 patients received 1 dose of lacosamide (96 as ﬁrst add-on, 360 as later add-on). In the
ﬁrst add-on cohort, 27/72 (37.5%) patients completed 12 weeks treatment and remained seizure-
free; 18/68 (26.5%) remained seizure-free after 24 weeks. 64/91 (70.3%) patients achieved 50%
reduction in seizure frequency during maintenance treatment. This was accompanied by a mean
7.1  16.00 point improvement from Baseline in the Quality of Life Inventory in Epilepsy (QOLIE-31-P)
total score for 24-week completers, with improvement reported in all subscales. Most common
treatment-emergent adverse events (TEAEs) were dizziness (31.3%) and headache (13.5%). In the later
add-on cohort, 39/261 (14.9%) and 29/249 (11.6%) patients remained seizure-free after completing 12
and 24 weeks’ treatment, respectively. 178/353 (50.4%) patients achieved 50% reduction in seizure
frequency during maintenance treatment. Mean change in QOLIE-31-P total score was 4.8  14.74 points
among 24-week completers. Common TEAEs were dizziness (33.6%), somnolence (15.0%) and headache
(11.4%).
Conclusions: Lacosamide initiated as ﬁrst add-on treatment was efﬁcacious and well tolerated in
patients with uncontrolled POS.
 2015 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nd/4.0/).1. Introduction
More than 30% of patients with epilepsy have been reported to
be unable to achieve remission despite appropriate antiepileptic
drug (AED) therapy [1].
Lacosamide is a newer AED, approved at dosages up to 400 mg/
day as monotherapy or adjunctive therapy in adults (17 years)rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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therapy in adults (16 years) with POS in the EU [3] and other
countries. The efﬁcacy and safety of adjunctive lacosamide have
been demonstrated in three randomised placebo-controlled trials
that recruited patients with uncontrolled POS [4–6]. Most patients
(84.4%) were taking multiple (two or three) concomitant AEDs,
with a lifetime use (started but previously discontinued) of >4
AEDs by 77.4% patients, and >7 AEDs by 45.2% patients [7].
Since the chance of seizure freedom declines signiﬁcantly with
subsequent AED regimens [8], it is of interest to assess the response
to adjunctive lacosamide when used earlier in treatment than in
the pivotal studies, such as ﬁrst add-on therapy. In this study, we
sought to evaluate the efﬁcacy and safety of lacosamide in two
populations of adults with POS using an evaluation schedule
similar to the registration trials. The ‘ﬁrst add-on’ cohort of
patients received lacosamide as their ﬁrst adjunctive treatment
after a ﬁrst monotherapy, while the ‘later add-on’ cohort had
previously been treated with at least two prior AED treatment
regimens before adding lacosamide.
2. Methods
This was a prospective open-label, non-randomised, Phase IIIb/IV
study (SP0954; NCT00955357), conducted between August 2009
and August 2013 at sites in Austria, Bulgaria, Czech Republic,
Denmark, Finland, France, Greece, Italy, Romania, Russia, Spain,
Turkey, Mexico and the USA, according to ICH-GCP [9], the
Declaration of Helsinki, and local laws of the countries involved.
All patients provided written informed consent and the study was
approved by an Ethics Committee or Institutional Review Board for
each site.
2.1. Patients
2.1.1. Overall study population
The study enrolled male or female adults (aged 18 years in
Mexico or Bulgaria, 17 years in the USA and 16 years in all other
countries). Patient enrolment criteria required a diagnosis of
epilepsy with simple partial seizures (SPS) and a motor component
or complex partial seizures (CPS) with or without secondarily
generalised seizures (sGS). The maximum permitted seizure
frequency (motor and non-motor) during the 12 weeks prior to
screening (Historical Baseline) was 40 POS per 28 days. Patients
were required to be lacosamide-naı¨ve and maintained on a stable
AED regimen for at least 7 days prior to screening, with or without
concurrent stable vagus nerve stimulation.
Patients were excluded if they had a seizure disorder char-
acterised primarily by POS without motor signs, a history of primary
generalised seizures or status epilepticus, uncountable seizures due
to clustering or possible non-epileptic seizures/events. Patients
were also excluded if they had any medical or psychiatric condition
that might compromise their health, ability to participate in the trial
or could interfere with lacosamide pharmacokinetics.
2.1.2. First add-on cohort
Patients included in the ﬁrst add-on cohort were taking an
appropriate ﬁrst monotherapy, deﬁned as a single AED taken for at
least 28 days prior to screening, and had no history of AED
polytherapy. Prior short-term intermittent rescue therapy was
accepted. At screening, patients had 24 months since epilepsy
diagnosis, and experienced 3 POS (SPS with motor signs, CPS or
sGS) at any time during the 12-week Historical Baseline.
2.1.3. Later add-on cohort
The later add-on cohort included patients with more treatment-
refractory epilepsy, who were taking 1–3 AEDs, had received 2prior AED treatment regimens (concurrently or sequentially), and
had been diagnosed with epilepsy at least 5 years before screening.
They had a POS frequency (SPS with motor signs, CPS or sGS) of 1
per 28 days during the 12-week Historical Baseline.
2.2. Treatment
The study design is shown in Supplemental Figure 1. Eligible
patients received open-label twice-daily oral treatment with
lacosamide tablets. Scheduled clinic visits were at screening (1
week before treatment initiation), and at Weeks 0 (treatment
initiation), 5, 6 (end of Titration Phase), 12, 18, 24 and 30 (End of
Maintenance Phase), followed by a Taper/Safety Follow-Up Phase
of up to 3 weeks.
During the 6-week Titration Phase, lacosamide was initiated at
100 mg/day (50 mg bid) and then increased by 100 mg/day/week
for 4 weeks to a maximum of 400 mg/day (200 mg bid). Changes to
concomitant AED treatment were not allowed until the end of
Weeks 4 and 5, when existing doses could be adjusted (no new AED
additions were permitted). A reduction in the lacosamide dosage to
300 mg/day was permitted (if required) at the end of Week 5.
One increase (to a maximum of 400 mg/day) or decrease (to a
minimum of 300 mg/day) of the lacosamide dose was allowed at the
end of Week 12 of the Maintenance Phase. No other change to the
lacosamide dose was permitted thereafter. Changes to concomitant
AEDs were not allowed at any time during the Maintenance Phase.
Patients who completed the 24-week Maintenance Phase and chose
not to continue receiving commercial lacosamide were gradually
tapered off.
2.3. Patient analysis sets
The Safety Set (SS) included all patients who received at least
one dose of lacosamide during the study. The full analysis set (FAS)
included patients of the SS who had at least one post-Baseline
seizure assessment. The Completer Set (CS) was deﬁned as patients
of the FAS who completed the ﬁrst 12 weeks of the Maintenance
Phase. Patients in the FAS who completed the 24-week Mainte-
nance Phase were considered 24-week completers.
2.4. Outcome measures and statistical analysis
The primary efﬁcacy outcome was the proportion of patients
among the CS who achieved seizure freedom, i.e. reported no
seizures, with no missing seizure data, during the ﬁrst 12 weeks of
the Maintenance Phase.
The proportion of patients who achieved seizure freedom
throughout the 24-week Maintenance Phase was also analysed
among 24-week completers. The percentage change in POS
frequency per 28 days was evaluated from Baseline to the ﬁrst
12 weeks of maintenance therapy among the CS, and at the end of
the 24-week Maintenance Phase in the FAS, using the last
observation carried forward (LOCF) method. Responder rates
(proportions of patients with 50% or 75% decrease in POS
frequency per 28 days from Baseline) were analysed after 12 weeks
of maintenance therapy among the CS, and at the end of the 24-
week Maintenance Phase in the FAS (LOCF).
Other efﬁcacy measures analysed among the FAS population
included the change in clinical status measured by the Clinical
Global Impression of Change (CGIC) and the Patient’s Global
Impression of Change (PGIC) at the end of the Maintenance Phase/
Early Discontinuation. The Quality of Life (QOL) Inventory in
Epilepsy-31-P (QOLIE-31-P) was completed by all capable patients
to assess the effects of treatment on activities of daily living and
overall health-related QOL across seven domains. The QOLIE-31-P
is an adaptation of the QOLIE-31, grouped into seven subscales and
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‘prioritisation’ for each subscale [10]. Total and subscale scores
range from 0 to 100, where higher scores indicate better QOL. Mean
change in QOLIE-31-P score from Baseline to the end of the 24-
week Maintenance Phase was analysed for 24-week completers
and the FAS using LOCF. Descriptive statistics were Cohen’s d-
effect size and p-values from paired t-tests. The proportion of
patients achieving clinically meaningful improvements in QOL was
estimated using previously deﬁned thresholds [11].
Safety was assessed for the SS based on treatment-emergent
adverse events (TEAEs), patient withdrawals due to TEAEs, vital
signs and laboratory evaluations.
Seizure freedom and safety data were also analysed for
subgroups of patients with or without concomitant use of one
or more of the following traditional sodium channel-blocking
(SCB) AEDs: carbamazepine, lamotrigine, oxcarbazepine, phenyt-
oin, ruﬁnamide and eslicarbazepine.
A descriptive analysis was used for all variables. Enrolment of
656 patients was planned and progressed more quickly for the
later add-on cohort than the ﬁrst add-on cohort. When recruitment
closed, the target patient number was not reached for the ﬁrst add-
on cohort. Direct comparison between the ﬁrst add-on and later
add-on cohorts was neither planned, nor conducted, in this study.
3. Results
Of 461 patients enrolled in the study, 456 received at least one
dose of lacosamide (SS), and 444 patients completed at least one
post-baseline seizure assessment (FAS) (Fig. 1). Five patients were
excluded from all analysis sets due to signiﬁcant conduct deﬁcien-
cies at one site. History of epilepsy and lifetime/concomitant AED
use reﬂected the enrolment criteria for each cohort (Table 1).
Concomitant SCB AEDs were taken by more patients in the later add-
on cohort (74.2%) than in the ﬁrst add-on cohort (54.2%).
3.1. First add-on cohort
Of 96 treated patients (SS), 80 (83.3%) completed the Titration
Phase, 72 (75.0%) completed the ﬁrst 12 weeks of the MaintenanceFig. 1. Patient ﬂPhase (CS), and 68 (70.8%) completed the 24-week Maintenance
Phase (24-week completers) (Fig. 1).
3.1.1. Efﬁcacy
Seizure freedom was achieved by 37.5% of patients in the ﬁrst
add-on cohort who completed the ﬁrst 12 weeks of the
Maintenance Phase and by 26.5% of 24-week completers
(Fig. 2A). POS frequency per 28 days decreased from Baseline to
Week 12 of the Maintenance Phase (median percent change
91.3% [range 100% to 343.9%], CS) and during the 24-week
Maintenance Phase (median change 90.5% [100% to 1720%],
FAS). This was associated with 50% responder rates of 76.4% after
12 weeks of maintenance therapy and 70.3% after 24 weeks
(Fig. 2B). Among the subgroup of patients taking SCB AEDs and
completing 12 weeks of maintenance therapy, 10/36 (27.8%)
achieved seizure freedom, while 4/33 (12.1%) patients remained
seizure-free after 24 weeks. Corresponding seizure freedom rates
among patients taking non-SCB AEDs were 17/36 (47.2%) and 14/
35 (40.0%).
At the end of treatment, clinicians rated patients’ clinical status as
improved for 73/86 (84.9%) patients in the ﬁrst add-on cohort (FAS),
comprising 20 patients (23.3%) considered very much improved, 41
(47.7%) much improved and 12 (14.0%) minimally improved
(Supplemental Figure 2). Few patients were considered to have
had no change (8/86, 9.3%) or worsened (5/86, 5.8%). A similar trend
was seen for the patient-reported PGIC, with 66/83 (79.5%) patients
indicating an improvement, comprising 21 (25.3%) very much
improved, 36 (43.4%) much improved and 9 (10.8%) minimally
improved; 9/83 patients (10.8%) had no change, and 8/83 (9.6%)
worsened.
3.1.2. Quality of life
Among 24-week completers in the ﬁrst add-on cohort there
was an improvement in overall QOL with a mean  SD change
from Baseline in QOLIE-31-P total score of 7.1  16.00 and an
associated Cohen’s d-effect size of 0.44 (Table 2), suggesting a
moderate improvement. Using pre-deﬁned thresholds [11], 49.2%
(32/65) of completers showed a clinically meaningful improvement
in the QOLIE-31-P total score (Supplemental Table 1). Improve-
ments were observed across all subscale scores, with the greatestow chart.
Table 1
Baseline characteristics (safety set).
First add-on
(N = 96)
Later add-on
(N = 360)
Age, mean  SD, years 41.0  17.08 38.9  12.34
Aged 18 years, n (%) patients 4 (4.2) 7 (1.9)
Aged 65 years, n (%) patients 10 (10.4) 4 (1.1)
Age range, min–max years 18–82 16–74
Female, n (%) patients 53 (55.2) 180 (50.0)
Body mass index, mean  SD, kg/m2 26.3  5.75 26.5  5.47
Racial group, n (%) patients
White 79 (82.3) 278 (77.2)
Black 1 (1.0) 19 (5.3)
Asian 0 12 (3.3)
Other/mixed 16 (16.7) 51 (14.2)
Time since diagnosis, years
Mean  SD 1.1  2.22 22.9  13.11
Median (range) 0.7 (0.0–21.2)a 21.2 (3.6–65.5)
Seizure classiﬁcation, n (%) patients
I. POSb 96 (100.0) 360 (100.0)
Simple partial with motor signs 29 (30.2) 112 (31.1)
Complex partial 57 (59.4) 259 (71.9)
Partial evolving to sGS 69 (71.9) 241 (66.9)
II. Generalised seizures, n (%) 0 3 (0.8)
POS frequency/28 days, median (range) 2.8 (0.9–67.1)c 3.7 (0.3–36.6)
Any lifetime AED use,d n (%) patients 7 (7.3)e 338 (93.9)
0 89 (92.7) 22 (6.1)
1 6 (6.3)e 63 (17.5)
2 1 (1.0)e 107 (29.7)
3 0 50 (13.9)
4 0 118 (32.8)
Number of concomitant AEDs, n (%) patients
0 1 (1.0)f 1 (0.3)g
1 95 (99.0) 100 (27.8)
2 0 170 (47.2)
3 0 87 (24.2)
4 0 2 (0.6)h
Most common concomitant AEDs at Baseline (10% of either cohort)
Valproate 28 (29.2) 91 (25.3)
Carbamazepine 25 (26.0) 107 (29.7)
Oxcarbazepine 15 (15.6) 74 (20.6)
Levetiracetam 12 (12.5) 99 (27.5)
Lamotrigine 7 (7.3) 66 (18.3)
Phenytoin 5 (5.2) 42 (11.7)
Topiramate 1 (1.0) 46 (12.8)
Any concomitant SCB use, n (%) patients 52 (54.2) 267 (74.2)
AED, antiepileptic drug; POS, partial-onset seizure; SCB, sodium channel blocker;
SD, standard deviation; sGS, secondarily generalised seizures.
a Two patients who had times since diagnosis of 21.2 and 6.3 years were initially
placed in the later add-on cohort, and were later moved to the ﬁrst add-on cohort
because they were taking a ﬁrst monotherapy.
b Patients may have experienced more than one type of seizure.
c One patient had a 28-day seizure frequency of >40 per month (motor and non-
motor) in the 3 months prior to the Screening Visit.
d All AEDs taken by a patient and stopped at least 28 days prior to Screening.
e Seven patients in the ﬁrst add-on cohort had at least one lifetime AED; these
included valproate and phenytoin (two patients each), and clonazepam, diazepam,
lamotrigine and carbamazepine (one patient each). One patient was listed as a
protocol deviation; for the other six patients, the AED was not considered to be
stable use.
f One patient was enrolled in the ﬁrst add-on cohort despite not taking any AEDs
at Baseline.
g One patient stopped taking lamotrigine on the date of the ﬁrst dose of
lacosamide, so not counted as a Baseline AED.
h Two patients had four concomitant AEDs at Baseline, but two of the
concomitant AEDs were coded as different preferred terms despite being the
same medication.
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Fig. 2. Seizure control, seen as (A) seizure freedom, and (B) responder rates
(proportions of patients achieving 50% or 75% reductions in seizure frequency
from Baseline).
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subscales, 40.0–53.8% of patients showed clinically meaningful
improvements. Similar results were noted for the FAS, with
the exception of medication effects (1.1  33.23 points from
Baseline); 39.8% of patients reported a clinically meaningful
improvement.3.1.3. Safety and tolerability
During the Treatment Phase, the mean duration of lacosamide
exposure in the ﬁrst add-on cohort was 168.4 days, and the median
mean exposure was 363.6 mg/day (Table 3).
TEAEs were reported for 69.8% of patients in the ﬁrst add-on
cohort, most frequently dizziness, headache, vertigo and nausea
(Table 3). Most TEAEs were mild or moderate in intensity; 10
patients (10.4%) experienced a severe TEAE. The overall incidence
of new-onset TEAEs was highest during the Titration Phase
(Table 4).
TEAEs were reported by 71.2% of patients taking SCB AEDs (37/
52) and 68.2% (30/44) of those taking non-SCB AEDs. The most
commonly reported TEAEs among SCB AED users were dizziness
(20/52, 38.5%), headache (7/52, 13.5%), vertigo (6/52, 11.5%),
nausea, inﬂuenza (each 5/52, 9.6%), somnolence, anxiety and
diplopia (each 4/52, 7.7%). The most commonly reported TEAEs
among patients taking non-SCB AEDs were dizziness (10/44,
22.7%), headache (6/44, 13.6%), vertigo, nausea, diplopia, depres-
sion, irritability and nasopharyngitis (each 3/44, 6.8%).
TEAEs led to study discontinuation of 12 (12.5%) patients in
the ﬁrst add-on cohort (Table 3). The most common TEAE leading
to discontinuation was dizziness, onset of which occurred during
Titration for all patients. Eleven patients discontinued due to
TEAEs with onset during the Titration Phase, 9 of who
discontinued during the Titration Phase. Eight (8.3%) patients
experienced serious adverse events (SAEs) and one patient
died during the study; following a subdural haematoma caused
by a fall, not considered by the investigator to be related to
treatment.
No effect of lacosamide as a ﬁrst add-on was observed for
neurological and vital signs, laboratory results or ECG.
Table 2
Change from baseline in QOLIE-31-P scores and subscales for patients adding lacosamide as a ﬁrst add-on or later add-on treatment (24-week Maintenance Phase
completers).
First add-on Later add-on
Baseline Change from
Baseline
P value Cohen’s
d-effect
size
Baseline Change from
Baseline
P value Cohen’s
d-effect
size
n Mean  SD n Mean  SD n Mean  SD n Mean  SD
Total score 68 60.5  15.93 65 +7.1  16.00 0.0007 0.44 245 59.7  16.62 239 +4.8  14.74 <0.0001 0.33
Seizure worry 68 44.4  27.47 65 +13.3  26.44 0.0001 0.50 248 43.9  25.58 246 +6.9  24.35 <0.0001 0.28
Overall QOL 68 60.0  17.51 65 +8.5  18.76 0.0005 0.46 248 61.4  18.12 247 +6.0  17.42 <0.0001 0.34
Emotional well-being 68 62.6  19.69 65 +8.1  22.00 0.0041 0.37 248 66.0  19.94 246 +2.4  18.90 0.45 0.13
Energy/fatigue 68 56.4  18.78 65 +8.3  20.85 0.0021 0.40 247 57.1  19.51 242 +3.4  19.27 0.0068 0.18
Cognitive 68 63.2  24.46 65 +5.5  21.68 0.045 0.25 248 61.8  23.75 247 +3.0  21.90 0.034 0.14
Medication effects 68 64.5  25.66 65 +4.1  28.96 0.26 0.14 247 59.9  26.44 245 +2.9  28.91 0.12 0.10
Social function 68 63.7  21.87 65 +4.7  27.09 0.16 0.17 247 59.0  25.04 246 +8.1  23.74 <0.0001 0.34
FAS, full analysis set; QOL, quality of life; SD, standard deviation. A positive change indicates an improvement. The P value is based on the paired t-test. Cohen’s d-effect size is
calculated by dividing the change from Baseline mean by the change from Baseline standard deviation.
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Of 360 treated patients (SS), 294 (81.7%) completed the
Titration Phase, 261 (72.5%) completed the ﬁrst 12 weeks of the
Maintenance Phase (CS) and 249 (69.2%) completed the 24-week
Maintenance Phase (24-week completers) (Fig. 1).
3.2.1. Efﬁcacy
Seizure freedom was achieved by 39 of 261 (14.9%) patients in
the later add-on cohort who completed the ﬁrst 12 weeks of the
Maintenance Phase, the majority of whom remained seizure-freeTable 3
Lacosamide exposure and safety proﬁle (safety set) during the treatment phase.
Parameter First add-on
(N = 96)
Later add-on
(N = 360)
Duration of lacosamide exposure, days 168.4  73.6 165.2  76.5
Mean  SD 210.0 (7–222) 210.0 (1–260)
Median (min–max)
Mean lacosamide exposure, median
(min-max), mg/day
363.6 (100–381) 373.9 (61–400)
Any TEAE, n (%) patients 67 (69.8) 265 (73.6)
TEAEs occurring in 5% patients in either cohort
Dizziness 30 (31.3) 121 (33.6)
Headache 13 (13.5) 41 (11.4)
Vertigo 9 (9.4) 22 (6.1)
Nausea 8 (8.3) 24 (6.7)
Diplopia 7 (7.3) 17 (4.7)
Somnolence 6 (6.3) 54 (15.0)
Anxiety 6 (6.3) 4 (1.1)
Inﬂuenza 5 (5.2) 4 (1.1)
Tremor 3 (3.1) 22 (6.1)
Vision blurred 2 (2.1) 24 (6.7)
Serious TEAEs, n (%) 8 (8.3) 17 (4.7)
Serious TEAEs reported by 2 patients
Convulsion 2 (2.1) 1 (0.3)
Dizziness 0 2 (0.6)
Pyrexia 0 2 (0.6)
Serious TEAEs of interest, n (%)
Agranulocytosis 0 1 (0.3)
Discontinuations due to TEAEs, n (%) 12 (12.5) 69 (19.2)
TEAEs leading to discontinuation of 2% patients of either cohort, n (%)
Dizziness 4 (4.2) 33 (9.2)
Headache 2 (2.1) 9 (2.5)
Convulsion 2 (2.1) 3 (0.8)
Depression 2 (2.1) 0
Somnolence 0 9 (2.5)
Deaths, n (%) 1a (1.0) 0
TEAE, treatment-emergent adverse event with onset during the Treatment Phase
(Titration or Maintenance), listed as Medical Dictionary for Regulatory Activities
(MedDRA) preferred terms; SD, standard deviation.
a Subdural haematoma, not considered to be related to study medication.(11.6%) for 24 weeks of maintenance therapy (Fig. 2A). POS
frequency per 28 days decreased from Baseline to Week 12 of the
Maintenance Phase (median percent change 54.8% [range
100% to 1668.7%], CS) and during the 24-week Maintenance
Phase (median change 50.9% [100% to 1720%], FAS). 50%
responder rates were 53.3% after 12 weeks of maintenance
therapy (CS) and 50.4% after 24 weeks (FAS; Fig. 2B). Among the
subgroup of patients taking SCB AEDs and completing 12 weeks of
maintenance therapy, 24/188 (12.8%) achieved seizure freedom,
while 19/178 (10.7%) remained seizure-free after 24 weeks.
Corresponding seizure freedom rates among patients taking non-
SCB AEDs were 15/73 (20.5%) after 12 weeks and 10/71 (14.1%)
after 24 weeks.
At the end of treatment, clinicians rated patients’ clinical status
as improved for 253/346 (73.1%) patients in the later add-on cohort
(FAS), comprising 56 patients (16.2%) considered very much
improved, 129 (37.3%) much improved and 68 (19.7%) minimally
improved (Supplemental Figure 2). There was no change for 51/
346 (14.7%) patients, and worse status for 42/346 (12.1%).
Similarly, 231/326 (70.9%) patients indicated an improvement in
PGIC (including 59 [18.1%] very much improved, 108 [33.1%] much
improved and 64 [19.6%] minimally improved), while 47/326
patients (14.4%) rated no change and 48/326 patients [14.7%]
worsened.
3.2.2. Quality of life
Among 24-week completers in the later add-on cohort there
was an improvement in overall QOL with a mean  SD change from
Baseline in QOLIE-31-P total score of +4.8  14.74 points and an
associated Cohen’s d-effect size of 0.33 (Table 2). Using pre-deﬁned
thresholds [11], 43.1% of completers (103/239) showed clinically
meaningful improvements in the QOLIE-31-P total score (Supple-
mental Table 1). Improvements were observed across all subscales
with the greatest improvement for social function (+8.1  23.74
points from Baseline). Across all subscales, 36.0–53.7% of patients
showed clinically meaningful improvements. Similar results were
noted for the FAS, with the exception of medication effects
(2.4  30.28 points from Baseline); 37.5% of patients reported a
clinically meaningful improvement.
3.2.3. Safety and tolerability
Mean duration of lacosamide exposure during the Treatment
Phase in the later add-on cohort was 165.2 days, and median mean
exposure was 373.9 mg/day (Table 3).
TEAEs were reported for 73.6% of patients in the later add-on
cohort, most frequently dizziness, somnolence and headache
(Table 3). Most TEAEs were mild or moderate in intensity; 36
Table 4
Incidence of most common TEAEsa by study phase (safety set).
Incidence, n (%) First add-on (N = 96) Later add-on (N = 360)
Titration Maintenance
weeks 1–12
Maintenance
weeks 12–24
Titration Maintenance
weeks 1–12
Maintenance
weeks 12–24
Patients entering the study phase 96 80 72 360 294 261
Any TEAE with onset during study phase 58 (60.4) 25 (31.3) 16 (22.2) 236 (65.6) 89 (30.3) 59 (22.6)
Patients reporting the most common TEAEs,a with onset during respective study phase
Dizziness 28 (29.2) 3 (3.8) 1 (1.4) 109 (30.3) 20 (6.8) 6 (2.3)
Headache 8 (8.3) 6 (7.5) 1 (1.4) 37 (10.3) 8 (2.7) 2 (0.8)
Vertigo 8 (8.3) 1 (1.3) 0 17 (4.7) 2 (0.7) 3 (1.1)
Nausea 6 (6.3) 0 2 (2.8) 22 (6.1) 2 (0.7) 0
Diplopia 6 (6.3) 0 1 (1.4) 17 (4.7) 1 (0.3) 0
Somnolence 5 (5.2) 2 (2.5) 0 51 (14.2) 4 (1.4) 3 (1.1)
Anxiety 4 (4.2) 1 (1.3) 1 (1.4) 4 (1.1) 0 0
Inﬂuenza 3 (3.1) 1 (1.3) 1 (1.4) 2 (0.6) 0 2 (0.8)
Tremor 2 (2.1) 0 1 (1.4) 21 (5.8) 2 (0.7) 0
Vision blurred 2 (2.1) 0 0 21 (5.8) 2 (0.7) 1 (0.4)
TEAE, treatment-emergent adverse event.
a TEAEs with overall incidence of over 5% in either cohort during the Treatment Phase (Titration plus Maintenance Phase).
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of new-onset TEAEs was highest in the Titration Phase (Table 4).
TEAEs were reported by 76.4% of patients taking SCB AEDs (204/
267) and 65.6% (61/93) of those taking non-SCB AEDs. The most
commonly reported TEAEs among SCB AED users were dizziness
(103/267, 38.6%), somnolence (36/267, 13.5%), headache (33/267,
12.4%), vision blurred (21/267, 7.9%), vertigo (20/267, 7.5%), nausea
(18/267, 6.7%) and diplopia (16/267, 6.0%). The most commonly
reported TEAEs among users of non-SCB AEDs were dizziness,
somnolence (each 18/93, 19.4%), tremor (9/93, 9.7%), headache (8/
93, 8.6%), nausea, irritability and urinary tract infection (each 6/93,
6.5%).
TEAEs led to study discontinuation of 69 (19.2%) patients in the
later add-on cohort (Table 3): 46 (12.8%) patients discontinued due
to TEAEs during the Titration Phase, 20 (5.6%) discontinued during
the ﬁrst 12 weeks of the Maintenance Phase and three (0.8%)
during the last 12 weeks of the Maintenance Phase. The most
common TEAE leading to discontinuation was dizziness, which had
an onset during Titration for 29/33 patients.
Seventeen (4.7%) patients in the later add-on cohort experi-
enced SAEs (Table 3). The incidence of TEAEs involving haema-
tology and clinical chemistry values was low, including one
serious TEAE of agranulocytosis, and two clinical chemistry-
related SAEs (hypochloraemia and hyponatraemia, both not
considered treatment-related and occurred in the same patient).
The event of agranulocytosis occurred in a 25-year-old male
patient who had been on study medication for 46 days and was
taking 400 mg/day lacosamide adjunctive to lamotrigine and
levetiracetam at the time of the event. The SAE was classiﬁed as
related to lacosamide treatment, which was discontinued. The
TEAE resolved in 7 days. There was one clinically signiﬁcant ECG
abnormality (a SAE of ST elevation, considered possibly related to
study medication and leading to discontinuation of 100 mg/day
lacosamide, taken adjunctive to carbamazepine and levetirace-
tam). No consistent or clinically relevant effect of lacosamide as a
later add-on was observed for neurological and vital signs, or
laboratory results.
4. Discussion
Lacosamide has been extensively evaluated in difﬁcult-to-treat
patients. The results of this study indicated that lacosamide is also
efﬁcacious as a ﬁrst add-on treatment for uncontrolled POS.
The antiepileptic efﬁcacy achieved with ﬁrst add-on lacosamide
supports previous studies of early lacosamide use, with 26.5% of
patients remaining seizure-free over 24 weeks of maintenancetherapy and 70% responding with 50% reductions in seizure
frequency. Although a potential limitation of this study is the 6-
month duration for evaluation of seizure freedom (in accordance
with the ILAE consensus deﬁnition, 12 months is typically required
among patients with treatment-refractory epilepsy [12]), similar
ﬁndings were observed in the non-interventional VITOBA study,
where lacosamide initiated as an add-on to monotherapy for POS
led to seizure freedom during the ﬁnal 3 months of the 6-month
study in 45.5% of 494 patients taking in-label doses, and 72.5% of
patients showed a 50% response [13]. In that study, of the 190
patients who received lacosamide after ﬁrst monotherapy, 60.5%
became seizure-free and 82.1% showed 50% response. Somewhat
lower seizure freedom and 50% response rates were seen among
the 304 patients who had received more than one previous AED
[13]. Despite differences in the deﬁnition of seizure freedom, the
retrospective, observational LACO-EXP study also reported that the
proportion of 50% responders during lacosamide therapy
progressively declined with increasing numbers of prior AEDs
[14]. Prospective audits of lacosamide and other newer agents
support these ﬁndings, showing seizure freedom was more
commonly achieved in patients treated for uncontrolled POS
when added as a ﬁrst or second add-on [15].
Interpretation of the ﬁndings from this study is limited by the
open-label, non-randomised design, and the failure to enrol the
target number of patients in the ﬁrst add-on cohort. This resulted
in an imbalance in patient numbers between the two cohorts.
Direct comparison between ﬁrst-add-on and later add-on cohort
was neither planned nor possible.
In the current study, 11.6% of patients who added lacosamide
later in their therapy achieved seizure freedom for 24 weeks after
initiating lacosamide treatment. This was somewhat higher than
the 3.3% of patients in registration trials who took 400 mg/day
lacosamide adjunctive to 1–3 AEDs (83.3% 2–3 AEDs) for 16–18
weeks [4–6]. A 50% reduction in seizure frequency was reported
by 50.4% of patients in the current study, also higher than that
observed for patients who took 400 mg/day lacosamide in the
registration trials (39.7%) [7]. Although the duration of epilepsy
was comparable for patients in this study and those in the
registration trials, later add-on patients in the current study
reported fewer lifetime AEDs (32.8% vs. 77.4% had used at least 4
AEDs) and had a lower median Baseline seizure frequency (3.7 vs.
11.5/28 days). Nonetheless, it should be noted that use of a
retrospective Baseline in this study may have underestimated the
Baseline seizure frequency compared with the prospective Base-
lines used in the registration trials. Responder and seizure freedom
rates comparable to those observed here have previously been
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patients. In the LACO-EXP study, 14.9% of patients taking
lacosamide at a median dosage of 400 mg/day were seizure-free
for the 12-month study, with 57.1% considered to be 50%
responders [14]. Poorer efﬁcacy outcomes are generally expected
from more refractory epilepsy populations [8,14,16,17], however,
ﬁndings from this study support a conclusion that improvements
in seizure frequency may be obtained with lacosamide treatment
taken as a ﬁrst or later add-on therapy.
The antiepileptic efﬁcacy of lacosamide was accompanied by
improvements in QOL and in patient- and physician-rated overall
clinical health status. In this study, mean changes in QOLIE-31-P
from Baseline and Cohen’s d-effect sizes showed improvements in
overall QOL both in study completers and the FAS, being
numerically higher in the ﬁrst add-on group. Across all QOLIE-
31-P subscales, clinically relevant improvements were observed in
40.0–53.8% of 24-week completers in the ﬁrst add-on cohort, when
assessed using pre-deﬁned thresholds [11]. An improvement in
medication effects was seen in 43.1% of completers, which,
alongside the 12.5% of patients discontinuing the study due to
AEs, supports the conclusion that 300–400 mg/day lacosamide was
well tolerated in this patient cohort. The greatest improvement
was observed for seizure worry, most likely reﬂecting the reduced
seizure frequency achieved in these patients. Among 24-week
completers in the later add-on cohort, clinically relevant improve-
ments were observed for in 36.0–53.7% of patients across all
QOLIE-31-P subscales. In the later add-on FAS population, QOLIE-
31-P scores were consistent with QOL improvements seen among
refractory patients in a Phase IIb trial (at 400 mg/day lacosamide,
assessed using the QOLIE-31 scale [4] and among responders to
lacosamide therapy in a pooled analysis [18]. These ﬁndings
suggest a positive effect on QOL with adjunctive lacosamide
therapy added early or later into the treatment paradigm.
Post hoc analyses of controlled studies in adults with focal
epilepsy have shown the pharmacokinetic proﬁle of lacosamide to
be unaffected by age (16–71 years) or gender [19], with
pharmacokinetic studies currently underway in paediatric patients
(including SP0847 [NCT00938431], SP0969 [NCT01921205] and
SP1047). However, evaluation of the safety and effectiveness of
lacosamide therapy among patient sub-groups in a setting which
more closely represents real-life clinical practice is of additional
interest, in particular, ﬁndings among patients adding lacosamide
to traditional SCB AEDs and in those taking AEDs with a different
mode of action. Some studies have reported similar seizure control
among these patient subgroups [13,20]. However, exploratory
analyses undertaken in the current study are consistent with other
reports [14,17,21,22] indicating that seizure freedom was more
achievable in patients adding lacosamide to treatment regimens
which do not include traditional SCB AEDs. This was particularly
true in patients who added lacosamide to a ﬁrst AED. Although
lacosamide is not a traditional SCB AED, these ﬁndings may be
attributed to the ability of lacosamide to selectively facilitate slow
inactivation of sodium channels [23]. However, due to the
uncontrolled nature of this study and the small numbers of patients
in each subgroup, caution should be applied when interpreting such
observations.
Alongside positive efﬁcacy ﬁndings and observed in improve-
ments quality of life, the safety proﬁle for lacosamide 300–400 mg/
day when initiated as a ﬁrst or later add-on therapy was consistent
with the known proﬁle for adjunctive lacosamide [4–6], with
tolerability improving over the study duration. Pharmacokinetic
assessments have shown lacosamide to have limited interactions
with a range of other AEDs, and consistent with previous studies,
the nature of the most commonly reported TEAEs were similar in
patients adding lacosamide to a regimen with or without a SCB
AED [2,7,21].5. Conclusion
The results of this study support the use of lacosamide as an
efﬁcacious and well-tolerated agent for the early treatment of
uncontrolled POS. They highlight the potential for a substantial
number of patients to achieve seizure freedom and marked
reductions in seizure frequency when treated with lacosamide as a
ﬁrst add-on therapy at doses of 300–400 mg/day.
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